R-Biopharm AG-医療機器分野:企業M&A・提携分析

◆英語タイトル:R-Biopharm AG - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011064
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
R-Biopharm AG (R-Biopharm), a subsidiary of Rohm GmbH is a clinical diagnostics center that test solutions for clinical diagnostics and food and feed analysis. The center offers test systems in the areas of infectological stool diagnostics, serological infection and allergy diagnostics for clinical diagnostics. It also provides food analysis test kits for the analysis of mycotoxins, antibiotics, hormones, genetically modified organisms, risk material, food allergens and microorganisms. R-Biopharm’s clinical products include allergy diagnostics, antibody detection, antigen detection, delayed food allergy, diagnostics, gastroenterology, histamine release, detection, molecular diagnostics and vitamin diagnostics. The center serves biotechnology and pharmaceutical industries. It has its presence in the UK, USA, Italy, France, Latin America, Brazil, Spain, Australia and China. R-Biopharm is headquartered in Darmstadt, Germany.

R-Biopharm AG – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
R-Biopharm AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
R-Biopharm AG, Medical Equipment Deals By Type, 2011 to YTD 2017 6
R-Biopharm AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
R-Biopharm AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
R-Biopharm AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
R-Biopharm AG, Medical Equipment, Deal Details 10
Partnerships 10
Gold Standard Diagnostics Enters into Distribution Agreement with R-Biopharm 10
R-Biopharm Enters into Agreement with HMNC Brain Health 11
R-Biopharm Enters into Agreement with Merck 12
Apogenix Enters into Agreement with R-Biopharm 13
PROGEN Biotechnik Enters Into Distribution Agreement With Mitsubishi Chemical 14
Acquisition 15
R-Biopharm Acquires Majority Stake In Humatrix 15
R-Biopharm AG – Key Competitors 16
R-Biopharm AG – Key Employees 17
R-Biopharm AG – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 20
Product News 20
Jul 21, 2016: RIDA SMART APP: New update for mycotoxin app 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
R-Biopharm AG, Medical Equipment, Key Facts 2
R-Biopharm AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
R-Biopharm AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
R-Biopharm AG, Medical Equipment Deals By Type, 2011 to YTD 2017 6
R-Biopharm AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
R-Biopharm AG, Deals By Market, 2011 to YTD 2017 8
R-Biopharm AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Gold Standard Diagnostics Enters into Distribution Agreement with R-Biopharm 10
R-Biopharm Enters into Agreement with HMNC Brain Health 11
R-Biopharm Enters into Agreement with Merck 12
Apogenix Enters into Agreement with R-Biopharm 13
PROGEN Biotechnik Enters Into Distribution Agreement With Mitsubishi Chemical 14
R-Biopharm Acquires Majority Stake In Humatrix 15
R-Biopharm AG, Key Competitors 16
R-Biopharm AG, Key Employees 17
R-Biopharm AG, Subsidiaries 18

★海外企業調査レポート[R-Biopharm AG-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trent Ltd (TRENT):企業の財務・戦略的SWOT分析
    Trent Ltd (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Univalor-製薬・医療分野:企業M&A・提携分析
    Summary Univalor is a university technology transfer organization which optimizes research outcomes by commercializing the technological innovations of researchers from academic institutions and health centers. The organization offers researcher services such as evaluating the technical feasibility …
  • Fukoku Mutual Life Insurance Company:企業の戦略・SWOT・財務分析
    Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • MTR Corporation Ltd:戦略・SWOT・企業財務分析
    MTR Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary MTR Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Santa Fe Group A/S:企業の戦略・SWOT・財務情報
    Santa Fe Group A/S - Strategy, SWOT and Corporate Finance Report Summary Santa Fe Group A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CEL-SCI Corp (CVM)-製薬・医療分野:企業M&A・提携分析
    Summary CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biologi …
  • International Paper Co:戦略・SWOT・企業財務分析
    International Paper Co - Strategy, SWOT and Corporate Finance Report Summary International Paper Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Banco de Sabadell SA:企業の戦略・SWOT・財務情報
    Banco de Sabadell SA - Strategy, SWOT and Corporate Finance Report Summary Banco de Sabadell SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Penta-Ocean Construction Co Ltd
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tokyo Broadcasting System Holdings Inc (9401):企業の財務・戦略的SWOT分析
    Tokyo Broadcasting System Holdings Inc (9401) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Nexteer Automotive Group Ltd:企業の戦略・SWOT・財務情報
    Nexteer Automotive Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Nexteer Automotive Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Larsen & Toubro Limited:企業の戦略・SWOT・財務情報
    Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report Summary Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Reliance Communications Limited:企業の戦略・SWOT・財務分析
    Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • OncoSec Medical Inc (ONCS)-製薬・医療分野:企業M&A・提携分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Personal Genome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • Huge China Holdings Limited (428):企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Northern Superior Resources Inc (SUP):企業の財務・戦略的SWOT分析
    Summary Northern Superior Resources Inc (Northern Superior) formerly Superior Diamonds Inc, is a mineral exploration company. The company's activities include acquisition and development of gold, and other mineral properties. Its projects include Croteau Est gold property, LAC surprise gold property …
  • iTeos Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報
    Summary iTeos Therapeutics SA (iTeos) is a biotechnology company that develops novel cancer immunotherapies. The company’s pipeline products include small molecule immunomodulators targeting IDO1, A2A, immune check points, STING agonist, and antibodies directed to TIGIT and Galectin 3. It also devel …
  • Applied Genetic Technologies Corp (AGTC):企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pi …
  • Telekom Malaysia Berhad (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Berhad (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆